GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

GeneDx has appointed Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.

As Chief Precision Medicine Officer, Lee will lead GeneDx’s work to empower customizable precision medicine as the standard of care, leveraging the power of genomics to predict, prevent, and optimize health outcomes throughout a person’s lifetime.

She will work closely with policymakers, health systems, biopharmaceutical companies, advocacy groups, payers, and global thought leaders to accelerate the adoption of precision medicine throughout healthcare.

“Dr. Lee is a visionary who brings together clinical care, scientific rigor, policy experience, and a deep sense of humanity,” said Katherine Stueland, President and CEO, GeneDx. “Her leadership will help shape the next frontier for GeneDx as we champion the future of precision medicine and drive a future where genomic insights guide healthier futures at the earliest moment possible, empowering families and informing proactive care across healthcare.”

Experience

Lee joins GeneDx from the Advanced Research Projects Agency for Health (ARPA-H), where she designed and directed high-impact public-private programs to accelerate individualized genetic medicines. A physician–scientist, neurosurgeon, and board-certified anesthesiologist, she brings more than two decades of leadership across academia, biotechnology, and global industry, including senior executive roles at Samsung Bioepis, Novartis Institutes of Biomedical Research, and BioMarin.

Lee earned her MD-PhD in Neuroscience from the Albert Einstein College of Medicine as part of the NIH Medical Scientist Training Program. She holds an AB in Chemistry and East Asian Languages and Civilizations from Harvard University, completed her residency training at Washington University School of Medicine in St. Louis and UCSF, and holds additional certifications in Bioethics (Columbia University) and Psychedelic-Assisted Therapy (California Institute of Integral Studies).

Lee remarked, “I’m honored to join a company that not only leads in genomic data and diagnostics but also has the courage and forward-looking perspectives to reimagine what precision medicine can be for generations to come.”